Back to Search
Start Over
Response to treatment in NMOSD: the Australasian experience
- Source :
- Multiple Sclerosis and Related Disorders; 20210101, Issue: Preprints
- Publication Year :
- 2021
-
Abstract
- •Retrospective study of treatment outcomes in AQP4 Ab positive NMOSD.•Rituximab is associated with reduced ARR compared to no treatment, beta-interferon and standard immunosuppressive therapy.•Compared to other therapies rituximab reduces risk in time to first relapse survival analyses.•Rituximab and immunosuppressive therapy are associated with a lower final EDSS score.•Rituximab should be considered as first-line therapy in AQP4 Ab positive NMOSD.
Details
- Language :
- English
- ISSN :
- 22110348
- Issue :
- Preprints
- Database :
- Supplemental Index
- Journal :
- Multiple Sclerosis and Related Disorders
- Publication Type :
- Periodical
- Accession number :
- ejs58311398
- Full Text :
- https://doi.org/10.1016/j.msard.2021.103408